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Abstract: Enhanced vascularization is critical to the treat-
ment of ischemic tissues and the engineering of new tissues
and organs. We have investigated whether sustained and
localized delivery of vascular endothelial growth factor
(VEGF) combined with transplantation of human microvas-
cular endothelial cells (HMVECs) can be used to engineer
new vascular networks. VEGF was incorporated and re-
leased in a sustained manner from porous poly(lactic-co-
glycolic acid) (PLG) matrices to promote angiogenesis at the
transplantation site. VEGF could be incorporated and re-
leased in a biologically active form from PLG matrices, with
the majority of VEGF release (64%) occurring within 2
weeks. These matrices promoted a 260% increase in the den-
sity of host SCID mouse-derived capillaries invading the
matrices after 7 days of implantation, confirming the activity
of the released VEGF. HMVECs were transplanted into
SCID mice on PLG matrices, and organized to form imma-
ture human-derived vessels within 3 days. Functional ves-
sels were observed within 7 days. Importantly, when
HMVECs were transplanted on VEGF-releasing matrices, a
160% increase in the density of human-derived blood vessels
was observed after 14 days. These findings suggest that
combining elements of vasculogenesis and angiogenesis
provides a viable and novel approach to enhancing local
vascularization. © 2002 Wiley Periodicals, Inc. J Biomed
Mater Res 60: 668–678, 2002
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INTRODUCTION
There exists a critical need to promote angiogenesis
in a variety of clinical situations, including the devel-
opment of collateral vascularization in cases of tissue
ischemia, wound healing, and in the emerging field of
tissue engineering. Two potential routes exist to pro-
mote blood vessel development: (1) encourage new
vessels to sprout from preexisting vessels in the native
tissue with growth factors (angiogenesis), (2) trans-
plant cells capable of differentiating into new vessels,
in essence mimicking the process of vasculogenesis. In
the nearly 30 years since Folkman1 first suggested a
relationship between neovascularization and angio-
genic molecules, tremendous progress has been made
in understanding the process of angiogenesis.2 This
understanding, coupled with the isolation and recom-
binant expression of angiogenic growth factors, has
allowed many research groups to demonstrate the fea-
sibility of using growth factors to enhance, or pro-
mote, the development of blood vessels.3,4 Therapeu-
tic angiogenesis has already been used to successfully
increase the capacity of collateral vascularization in
cases of both peripheral5–7 and myocardial isch-
emia.8,9
Current studies of therapeutic angiogenesis deliver
angiogenic growth factors through either a single, or
repeated, injection directly into the circulation or tar-
get tissue to stimulate a response (e.g., migration, pro-
liferation) from the cellular component of preexisting
blood vessels. These approaches to delivery of growth
factor risk promoting unwanted blood vessel forma-
tion (e.g., at the site of quiescent tumors) and toxic side
effects.10–12 In addition, the bolus administration of
growth factor cannot maintain a consistent concentra-
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tion at the desired site of angiogenesis, as demon-
strated by vascular endothelial growth factor (VEGF),
which has been shown to have an elimination half-life
of less than 1 h following injection.8 Delivering angio-
genic growth factors utilizing controlled drug delivery
strategies,13,14 offers the potential to promote angio-
genesis at a specific site while leaving the circulation
free from high concentrations of growth factor.
A localized, sustained delivery strategy will
broaden the applications of therapeutic angiogenesis
to new fields, such as tissue engineering, in which
developing vascular beds is a critical challenge.14 Tis-
sue engineering seeks to bridge the gap between trans-
plant organ supply and demand by engineering new
functional tissues from relatively small cell popula-
tions.15 This general strategy to engineer tissues via
cell transplantation utilizes cells that have been iso-
lated from a patient and expanded in culture. One of
the most significant challenges facing this approach is
ensuring sufficient nutrient delivery to the trans-
planted cells. When cells are first transplanted into a
host, on three-dimensional porous matrices,16 the area
within the matrix is avascular and the transplanted
cells are dependent on the diffusion of nutrients and
waste for survival. This condition of limited transport
is adequate if the tissue is small (<1-mm thick) or the
cells’ metabolic needs are low (e.g., chondrocytes). In
the case of more metabolically demanding cell popu-
lations (e.g., hepatocytes), most cells die soon after
transplantation17 because of mass transport limita-
tions.18 Surrounding tissue from the host will natu-
rally invade the porous matrix,19 bringing blood ves-
sels, but this alone may be insufficient to provide nec-
essary nutrients to cells within the matrix. By inducing
the formation of additional blood vessels in these po-
rous matrices, it may ultimately be possible to enhance
the long-term survival of transplanted cells.14
Inductive means of engineering vascular networks
may be limited if the ability of host blood vessels to
respond to angiogenic molecules is compromised ei-
ther by disease (e.g., impaired wound healing in dia-
betes) or prior medical treatments (e.g., radiation
therapy). An alternative approach to neovasculariza-
tion involves directly transplanting vessel-forming
cells as a source for new blood vessels.20,21 Such vas-
culogenesis is normally observed only during devel-
opment,22 but recent studies have demonstrated the
feasibility of transplanting endothelial cells (ECs),21 or
their precursors,23 to form neovessels. Implanting the
cellular components of blood vessels may provide a
strategy to improve neovascularization in certain situ-
ations because fewer ECs may be required to migrate
from existing blood vessels.
This report addresses the possibility that localized
delivery of growth factors may allow one to form new
vascular beds in a localized region with a small total
dose of the angiogenic molecule. In addition, the effect
of locally delivered growth factors on blood vessel
formation by transplanted ECs is also investigated. It
is hypothesized that the released growth factors can
act upon the transplanted ECs to promote survival,
proliferation, and differentiation. We have developed
and demonstrated a new in vivo system capable of
sustained delivery of bioactive VEGF from a three-
dimensional cell transplantation matrix. The use of a
highly porous polymer matrix enables one to define
the area in which blood vessel development can be
observed and create a potential space for EC trans-
plantation. The controlled release of VEGF allowed
the implanted matrices to directly control the behavior
of the local cell populations and promoted the forma-
tion of blood vessels from both transplanted and na-
tive ECs.
MATERIALS AND METHODS
Matrix formation and characterization
A copolymer of D,L-lactide and glycolide (PLG) (85:15 mo-
lar ratio) (Boehringer Ingleheim, Germany) was used in a
gas foaming/particulate leaching process24,25 to form matri-
ces for VEGF and EC delivery. Granular PLG (5 mg; 106 mm
< d < 250 mm) was mixed with 0.25 mL of an aqueous 0.1%
alginate (ProNova, Oslo, Norway) solution, and 5 mg of
VEGF165 (Intergen, Purchase, NY). The samples were lyoph-
ilized to form a powder, mixed with 100 mg of NaCl (250
mm < d < 425 mm), compression molded into a disk (diam-
eter 4.2 mm, thickness 3 mm), and foamed as previously
described.24,25 Control matrices with 0, 0.25, 0.5, 1, and 2 mL
of the 0.1% alginate solution, mentioned above, were also
manufactured. The NaCl particles were leached from the
matrices, and any alginate present was crosslinked, by im-
mersing each matrix in 0.1M CaCl2 for 24 h. Matrices fabri-
cated with this process using similar conditions have previ-
ously been documented to exhibit a porosity of 95%, and an
average pore size of 190 mm.24
For scanning electron microscopy examination of the po-
rous matrices, samples were dried and sputter-coated with
gold. The permeability of the matrices’ porous structure to
cells was next examined by seeding matrices processed with
0, 5, 10, 20, and 40 (w/w) % alginate (n = 5) with 3 × 106
human (dermal) microvascular endothelial cells (HMVECs)
(Cascade Biologics, Portland, OR) suspended in 50 mL of a
1:1 mixture of medium 131 (Cascade Biologics) and growth
factor-reduced Matrigelt (Becton Dickinson, Bedford, MA).
Each matrix was allowed to absorb the cell suspension for 5
min in a 30-mm Petri dish. The matrices were then removed
from the dish and any cells remaining in the dish were
counted in a ZM Coulter Counter (Coulter Electronics, Hi-
aleah, FL) to ultimately determine the number of cells
seeded into each matrix. The mechanical properties of the
matrices (n = 10) were measured with an MTS compression
tester (MTS, Minneapolis, MN) as previously described.24
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In vitro release and characterization of VEGF
To determine the efficiency of incorporation and the ki-
netics of VEGF release, 0.3 mCi of 125I-labeled human recom-
binant VEGF165 (100 mCi/mg) (Biomedical Technologies Inc.,
Stoughton, MA) was added to samples (n = 5) as a tracer.26
Biological activity of the released VEGF was confirmed by
placing VEGF-releasing matrices (n = 5), supported in tran-
swells (12-mm, 3-mm pore diameter) (Corning, Cambridge,
MA) into the media, directly over HMVECs actively grow-
ing in cell culture wells of a 12-well plate (10,000 cells
seeded/well) (Corning). After 72 h, before confluence was
observed, the cultured cells were trypsinized to remove
them from the dish and counted with a Coulter counter. The
matrices in transwells were then moved to wells freshly
seeded with 10,000 HMVECs and allowed to incubate for an
additional 72 h. The magnitude of growth stimulation was
compared with control conditions in which cells were cul-
tured in the presence of matrices containing no VEGF and
with known concentrations of VEGF.
In vivo studies
Matrices (n = 4) were implanted in subcutaneous pockets
(two per animal) on the dorsal region of 32, 7–9-week-old
male SCID mice (cb17/SCID) (Taconic Labs, Germantown,
NY). Matrices were sterilized in all experiments by immer-
sion in 100% ethanol followed by a series of rinses (4 × 15
min each) in phosphate buffered saline. All NIH guidelines
for the care and use of laboratory animals (NIH Publication
no. 85-23 Rev. 1985) were observed. Animals were anesthe-
tized with an intramuscular injection of ketamine (87 mg/
mL) and xylazine (2.6 mg/mL). For conditions including
transplanted cells, immediately before matrix implantation,
3 × 106 HMVECs were suspended in 50 mL of a 1:1 mixture
of medium 131 and growth factor-reduced Matrigel, and
allowed to absorb into the polymer matrix 5 min. Matrices
were retrieved after 3, 5, 7, and 14 days, embedded in par-
affin, and sectioned for histologic examination. Sections
were either stained with Gill 3 hematoxylin (Sigma, St.
Louis, MO) and eosin (Sigma), or immunostained with an-
tibodies raised against human CD34 (QBEnd 10, diluted 1:
10) (Lab Vision, Fremont, CA), human CD31 (JC/70A, di-
luted 1:10) (Dayko, Carpinteria, CA), and human von Will-
ebrand factor (polyclonal, diluted 1:2000) (Dayko) using a
standard protocol.21 Briefly, sections were deparaffinized
and washed for 5 min in 3% H2O2 (Sigma) to quench en-
dogenous peroxidases. The sections were then incubated for
10 min with terminator blocking solution (Biocare Medical,
Walnut Creek, CA) to prevent nonspecific antibody–antigen
interactions, and then allowed to incubate with the primary
antibody for 1.5 h at 37° C. For a secondary antibody, broad-
spectrum biotinylated universal link (Biocare Medical) was
used for 20 min followed by a 15-min incubation with strep-
tavidin-HRP (Biocare Medical). The HRP reaction was com-
pleted with 3,38-diaminobenzidine (Zymed, South San Fran-
cisco, CA) for 30 s. The sections were then visualized at 200×,
400×, and 1000× with an E-800 light microscope (Nikon).
Four samples from each condition, with eight sections from
each sample, were analyzed with NIH Image software (de-
veloped by the US National Institutes of Health).
RESULTS
VEGF delivery system
A novel model system was next developed for the
sustained delivery of VEGF. We previously demon-
strated that VEGF can be incorporated and released
from polymer matrices,25 but the processing yielded a
poor efficiency of incorporation. A polysaccharide, al-
ginate, was included in the matrices in these studies,
in an effort to improve VEGF incorporation. Matrices
were first examined to determine the effects of the
alginate component on the matrices’ porous structure
for fear it could be negatively affected. Scanning elec-
tron micrographs of the PLG matrices with 5 (w/w) %
alginate showed an open porous polymer matrix in-
distinguishable from PLG matrices processed without
the addition of alginate [Fig. 1(A,B)] whereas the in-
clusion of 10, 20, or 40 (w/w) % alginate was observed
to occlude the porous structure of the matrices [Fig.
1(C–E)]. In addition, when HMVECs were seeded
onto matrices processed with various weight fractions
of alginate, the permeability of the matrices to cells
was observed to decrease as the alginate content was
increased [Fig. 1(F)]. The difference in cell seeding
measured between the 5 (w/w) % alginate conditions
and those without alginate were not statistically sig-
nificant. Matrices with 10, 20, and 40 (w/w) % alginate
were omitted from other experiments because of their
negative effects on the overall porous structure.
Inclusion of 5 (w/w) % of alginate into the matrices
led to an overall VEGF incorporation efficiency of 74 ±
3% whereas matrices lacking alginate demonstrated a
final incorporation of only 27 ± 3%. The elastic modu-
lus for 5 (w/w) % alginate-containing matrices was
287 ± 84 kPa, whereas matrices without alginate mea-
sured 182 ± 62 kPa, which is comparable to previous
reports24,25 and sufficient to resist compression in vivo.
When the data sets were compared, no statistically
significant difference (p > 0.05) was noted between the
two conditions. This result suggests that the inclusion
of 5 (w/w) % alginate had no significant effect on the
mechanical strength or structure of these matrices.
The ability of matrices to release the incorporated
VEGF in a sustained manner was next assessed in
vitro. The in vitro release profile of VEGF from all ma-
trix processing conditions demonstrated similar con-
trolled kinetics, with 40% of the VEGF released in the
first 24 h, an additional 10% being released in the sec-
ond 24 h, and 2%/day being released for the next 7
days [Fig. 2(A)]. After day 9, at which time 60% of the
VEGF had left the matrix, the release decreased to
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1%/day and continued for the remainder of the ex-
periment. This rapid release of VEGF satisfies our goal
of releasing the majority of the incorporated growth
factor within 2 weeks, because this covers the time
period in which the majority of transplanted cells die
before they become integrated with the host tissue.27
A critical issue for any delivery vehicle is whether the
growth factor has been denatured, or otherwise inac-
tivated, during incorporation or storage in the poly-
mer.28 The preservation of the VEGF’s biological ac-
tivity after incorporation and release was confirmed
with an in vitro cell-based assay. VEGF-releasing ma-
trices processed with 5 (w/w) % alginate and 5 mg
VEGF were allowed to release directly into tissue cul-
ture media in the presence of HMVECs. The released
VEGF induced a statistically significant increase in cell
proliferation in all times tested throughout 15 days of
release [Fig. 2(B)]. The released VEGF was >80% active
as compared with control VEGF, even at the last time
point tested.
To measure the physiological response induced by
the sustained and localized delivery of VEGF, matrices
processed with VEGF, and controls, were implanted
subcutaneously into SCID mice and retrieved after 7
and 14 days (Fig. 3). Histological sections from the
retrieved implants were stained with hematoxylin and
eosin to visualize the blood vessels present within the
matrices [Fig. 4(A–D)]. Blood vessel density was mea-
sured in the matrices and found to be approximately
260% greater in VEGF-releasing matrices, compared
with control samples, after 7 days, and 70% greater
after 14 days [Fig. 4(E)].
Figure 1. Scanning electron micrographs of PLG matrices processed with no alginate component (A), 5 (w/w) % alginate
(B), 10 (w/w) % alginate (C), 20 (w/w) % alginate (D), and 40 (w/w) % alginate (E). When 3 × 106 HMVECs were seeded onto
matrices (n = 5) with varying weight fractions of alginate, significantly fewer cells were observed to become settled onto the
matrices as the fraction of alginate was increased (F). The differences between the number of cells retained in 0% and 5%
alginate-containing matrices are not statistically significant.
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Combined VEGF delivery and EC transplantation
HMVECs were transplanted into SCID mice on ma-
trices to confirm our ability to engineer functional new
blood vessels from transplanted cells. Sections from
tissues removed at various times were stained for the
presence of CD34, CD31, and von Willebrand factor.
Positive CD34 and CD31 staining was specific to trans-
planted HMVECs, and found only within the space
defined by the polymer matrices. Positive von Will-
ebrand factor staining was observed only in large
mouse-derived blood vessels outside the tissue ac-
tively invading the matrices (not shown). The CD34
positively stained HMVECs clearly illustrate the time
course of blood vessel development from transplanted
ECs. Transplanted HMVECs are initially fully
rounded, but after 3 days, the cells within 100 mm of
the matrix boundary have begun to differentiate into
loosely defined large rounded structures [Fig. 5(A,B)].
After 5 days, these structures have compartmentalized
to form neovessels along the edge of mouse tissue,
which is invading the matrix, but no evidence of ves-
sel function can be found [Fig. 5(C)]. Mature human-
derived vessels carrying mouse blood are observed
after 7 and 14 days [Fig. 5(D,E)]. The pattern of CD31
staining (not shown) was indistinguishable from the
results obtained with CD34.
Finally, to determine whether it is possible to modu-
late the ability of transplanted HMVECs to form vas-
cular networks, HMVECs were transplanted into
SCID mice on matrices releasing biologically active
VEGF. Histological sections stained with anti-human
Figure 2. (A) Cumulative VEGF release in vitro (n = 5) from
5 (w/w) % alginate-containing matrices (•) and matrices
processed without alginate (s). Values represent mean and
standard deviation. (B) Biological activity of VEGF released
from 5 (w/w) % alginate-containing matrices (n = 6). Cul-
ture wells containing VEGF-releasing matrices showed a sta-
tistically significant (p < 0.05) increase in cell proliferation
when compared with the growth observed in control
samples. Values represent the fractional increase in cell
growth over and above the growth observed in control
samples.
Figure 3. Gross photomicrographs of typical VEGF-
releasing (A) and control (B) PLG matrices, 14 days after
implantation. [Color figure can be viewed in the online is-
sue, which is available at www.interscience.wiley.com.]
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CD34 antibodies were again used to measure the den-
sity of human-derived vessels in the matrices. No sta-
tistically significant difference between the control
(HMVECs, no VEGF) and experimental condition
(HMVECs and VEGF) was noted at 7 days. However,
after 14 days, the VEGF-releasing condition showed a
160% increase in human-derived vessel density, com-
pared with controls (Fig. 6). The lack of an effect at the
Figure 4. In vivo response to VEGF-releasing matrices (n = 4). Matrices were retrieved after 1 (A and B) and 2 (C and D)
weeks. Matrices releasing VEGF (B and D), and control samples (A and C), were photographed at original magnification 400×.
(E) The density of blood vessels, measured in each implant by manual counting at 200× magnification, was significantly
greater (p < 0.05) in VEGF-releasing matrices, compared with controls, at both time points. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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early time points likely reflects an inability of the
transplanted HMVECs to respond to the VEGF until
organized to some extent. The number of host-derived
blood vessels in the matrices was also quantified, and
sustained delivery of VEGF again led to increases in
the density of mouse-derived blood vessels at both 7
and 14 days. The magnitude of the mouse-derived
blood vessel density increases were similar to that
noted with VEGF delivery alone [Fig. 4(E)].
DISCUSSION
VEGF delivery and EC transplantation are promis-
ing approaches to promote therapeutic angiogenesis
for a number of clinical applications.29 We have de-
veloped a model system that allows for combined
VEGF delivery and EC transplantation. This system
demonstrates that sustained release of VEGF from
polymer matrices can increase the overall density of
Figure 5. Photomicrographs of blood vessels developing from transplanted HMVECs. (A) Matrix seeded with HMVECs,
and stained for human CD34 before implantation (original magnification ×400). Implanted matrices, with HMVECs retrieved
after 3 (B), 5 (C), 7 (D), and 14 days (E), stained for human CD34, and photographed at original magnification ×1000.Vessels
in (D) and (E) are functional as indicated by the presence of circulating red blood cells. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.com.]
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Figure 6. Human-derived blood vessel response to VEGF-releasing matrices. Matrices (n = 4/time point/condition) were
retrieved after 1 and 2 weeks. The density of HMVECs containing blood vessels in VEGF-releasing matrices increased
significantly (p < 0.05) at 14 days in comparison with no-VEGF matrices. No statistically significant difference exists between
the two conditions at the 7-day time point. [Color figure can be viewed in the online issue, which is available at www.
interscience.wiley.com.]
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blood vessels present in the tissue growing in and
around the matrix. In addition, this system demon-
strates that providing a local source for VEGF in-
creases the ability of transplanted HMVEC to integrate
into the host vasculature and form functional blood
vessels. These results suggest it may be possible to use
a polymer-based delivery system to engineer more ex-
tensive vascular networks and collateral vasculariza-
tion, or to create better environments for transplanted
cell survival and proliferation.
Using a localized sustained release system for
growth factors may greatly enhance the desired for-
mation of local blood vessels, while eliminating the
risk of toxic side effects12 and unwanted blood vessels
developing at other sites in the body. Localized deliv-
ery as opposed to systemic delivery limits the VEGF’s
area of effect because large masses of VEGF do not
enter the circulation. Sustained release at a local site
confers additional advantages to our VEGF delivery
system by further reducing the mass of VEGF needed
to promote the desired effects. In contrast, a continu-
ous introduction of new growth factor is used in an
effort to maintain a stable concentration in most pre-
viously published work.30,31 Free VEGF is rapidly
taken up by cells and degraded, or bound up by ex-
tracellular matrix molecules,5 which quickly decreases
the concentration of injected VEGF. For example, re-
peated intravenous injections of 45 mg of VEGF31 have
been shown to induce no significant physiological ef-
fect, whereas we have demonstrated that the con-
trolled release of only 3.75 mg of VEGF is able to pro-
mote a measurable and continuous increase in blood
vessel density for at least 2 weeks after implantation.
This increase in vascularization was noted within and
immediately adjacent to the scaffold. The dose of de-
livered VEGF was not varied in the current study.
However, we anticipate that as the delivered dose is
increased, the distance from the matrix within the sur-
rounding tissue that exhibited an increased blood ves-
sel density would rise in parallel. The magnitude of
the observed blood vessel density increase in this
study is comparable to other studies using systemic
delivery of up to 1 mg of VEGF.32,33
VEGF can be released in a controlled manner, from
the matrices, in an intact and biologically active form.
These newly developed matrices are physically indis-
tinguishable from the gas-foamed matrices previously
described.24 In addition, they demonstrate improved
VEGF incorporation and release kinetics compared
with previously developed VEGF-delivery matrices.25
It is possible that the inclusion of alginate in the PLG
matrices may alter the VEGF presentation to the target
cells (e.g., released VEGF may be complexed with al-
ginate chains). However, the release kinetics of VEGF
from scaffolds was similar with or without alginate
(Fig. 2), and the bioactivity of VEGF released from
alginate-containing matrices was similar to that previ-
ously measured when VEGF was released from algi-
nate-free matrices.25 Our goal in this study was for the
VEGF to be released relatively rapidly. The release of
the incorporated VEGF is observed to occur in vitro as
a large initial burst followed by a slower sustained
release of the remaining factor. The initial release is
likely due to the dissolution of lyophilized VEGF ab-
sorbed to the surface of the PLG, or release of VEGF
contained within surface-accessible pores. The subse-
quent slower release rate is likely controlled by deg-
radation of the PLG and diffusion of the VEGF
through the matrix. In any case, it is probable that the
significant burst observed in vitro is attenuated in vivo
because of the absence of buffer solution washing
completely through the porous matrix. In addition, the
matrices are surrounded by wounded tissue after im-
plantation, where plasma proteins freely adsorb onto
the matrix and fibrovascular tissue rapidly grows into
the porous openings along the matrix surface. These
environmental changes will likely alter the degrada-
tion rate of the polymer matrix and limit the diffusion
distance of the released VEGF.
HMVECs transplanted on PLG matrices were able
to form new blood vessels. The transplanted cells rap-
idly joined with the host vasculature to form hybrid
vessels without outside stimulus, but when this same
experiment was repeated with a VEGF-releasing ma-
trix, the result was a significant increase in the number
of blood vessels derived from transplanted EC within
14 days. In this case, the effect of the VEGF is likely
two-fold. It may contribute both to the survival of the
transplanted cells via the activation of apoptosis sup-
pression genes,34,35 and encourage EC differentiation
into neovessels. It is important to note that the deliv-
ery of VEGF alone led to a dramatic increase in host-
derived blood vessels invading the matrix space, and
the density of host-derived blood vessels was approxi-
mately one order of magnitude higher than the den-
sity of blood vessels formed by transplanted ECs.
However, in situations in which the host tissue has a
compromised ability to respond to angiogenic factors,
it may be necessary to provide ECs within the scaffold
to enhance neovascularization. In addition, transplan-
tation of genetically modified ECs may be useful as an
approach to deliver macromolecular drugs to the sys-
temic circulation. In either of these situations, it will
clearly be desirable to maximize the integration of the
transplanted ECs with the host vasculature.
Drug-releasing matrices capable of cell transplanta-
tion represent a potentially powerful new model of
vascularization, with the ability to control which cell
types are presented at a site and the local concentra-
tion of both promoters and inhibitors of angiogene-
sis.25,36 By virtue of the matrices’ spatial and temporal
control over drug release, greater insight might be
gained into the complex and dynamic process of an-
giogenesis and vasculogenesis for cancer research as
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well as tissue engineering applications. When com-
pared with other methods of controlled drug delivery
(e.g., microspheres), drug-releasing scaffolds have
several advantages. Porous PLG matrices create and
define a space for study, and have been shown to
provide an effective support for the growth of a vari-
ety of transplanted cells and tissues, including tu-
mors.36 This grants researchers the ability to easily
incorporate any cell type, or even genetically modified
cells, into the experimental system. Blood vessel de-
velopment can be followed in either transplanted ECs
or precursors, and ECs originating from host blood
vessels.21 These drug-releasing matrices will become
even more valuable as investigators continue to iden-
tify and implicate new molecules in the angiogenic
cascade. Recently, attention has focused on the tem-
poral importance of growth factor presentation in an-
giogenesis.37 Drug-releasing polymer matrices also of-
fer the potential to release a combination of growth
factors from a single matrix. These systems may
broadly aid in understanding the biochemical path-
ways that depend on a number of simultaneously or
sequentially delivered soluble signals.
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